These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 24018103)

  • 1. Association study of the vesicular monoamine transporter gene SLC18A2 with tardive dyskinesia.
    Zai CC; Tiwari AK; Mazzoco M; de Luca V; Müller DJ; Shaikh SA; Lohoff FW; Freeman N; Voineskos AN; Potkin SG; Lieberman JA; Meltzer HY; Remington G; Kennedy JL
    J Psychiatr Res; 2013 Nov; 47(11):1760-5. PubMed ID: 24018103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors.
    Niemann N; Jankovic J
    Drugs; 2018 Apr; 78(5):525-541. PubMed ID: 29484607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence for association of the GLI2 gene with tardive dyskinesia in patients with chronic schizophrenia.
    Greenbaum L; Alkelai A; Rigbi A; Kohn Y; Lerer B
    Mov Disord; 2010 Dec; 25(16):2809-17. PubMed ID: 20939080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Support for association of HSPG2 with tardive dyskinesia in Caucasian populations.
    Greenbaum L; Alkelai A; Zozulinsky P; Kohn Y; Lerer B
    Pharmacogenomics J; 2012 Dec; 12(6):513-20. PubMed ID: 21808285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxidative stress and tardive dyskinesia: pharmacogenetic evidence.
    Cho CH; Lee HJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Oct; 46():207-13. PubMed ID: 23123399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetics of tardive dyskinesia: Promising leads and ways forward.
    Zai CC; Maes MS; Tiwari AK; Zai GC; Remington G; Kennedy JL
    J Neurol Sci; 2018 Jun; 389():28-34. PubMed ID: 29502799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia.
    Basile VS; Ozdemir V; Masellis M; Meltzer HY; Lieberman JA; Potkin SG; Macciardi FM; Petronis A; Kennedy JL
    Mol Psychiatry; 2001 Mar; 6(2):230-4. PubMed ID: 11317228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of the orphan nuclear receptor NR4A1 with tardive dyskinesia.
    Novak G; Gallo A; Zai CC; Meltzer HY; Lieberman JA; Potkin SG; Voineskos AN; Remington G; Kennedy JL; Levesque D; Le Foll B
    Psychiatr Genet; 2010 Feb; 20(1):39-43. PubMed ID: 20010315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia.
    Dorfman BJ; Jimenez-Shahed J
    Expert Rev Neurother; 2021 Jan; 21(1):9-20. PubMed ID: 33174440
    [No Abstract]   [Full Text] [Related]  

  • 10. Valbenazine for the treatment of tardive dyskinesia.
    Barquero N
    Drugs Today (Barc); 2016 Dec; 52(12):665-672. PubMed ID: 28276538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathway-based association analysis of genome-wide screening data suggest that genes associated with the gamma-aminobutyric acid receptor signaling pathway are involved in neuroleptic-induced, treatment-resistant tardive dyskinesia.
    Inada T; Koga M; Ishiguro H; Horiuchi Y; Syu A; Yoshio T; Takahashi N; Ozaki N; Arinami T
    Pharmacogenet Genomics; 2008 Apr; 18(4):317-23. PubMed ID: 18334916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No association between dopamine D4 receptor gene -521 C/T polymorphism and tardive dyskinesia in schizophrenia.
    Lee HJ; Kang SG; Choi JE; Paik JW; Kim YK; Kim SH; Lee MS; Joe SH; Jung IK; Kim L
    Neuropsychobiology; 2007; 55(1):47-51. PubMed ID: 17556853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacogenetic assessment of antipsychotic-induced tardive dyskinesia: contribution of 5-hydroxytryptamine 2C receptor gene and of a combination of dopamine D3 variant allele (Gly) and MnSOD wild allele (Val)].
    Zhang Z; Hou G; Zhang X; Yao H; Sha W; Zhang X
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2003 Apr; 20(2):98-102. PubMed ID: 12673575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Vesicular Monoamine Transporter 2 Inhibitors in Tardive Dyskinesia Management.
    Sreeram V; Shagufta S; Kagadkar F
    Cureus; 2019 Aug; 11(8):e5471. PubMed ID: 31641566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder.
    Kane JM; Correll CU; Liang GS; Burke J; O'Brien CF
    Psychopharmacol Bull; 2017 Aug; 47(3):69-76. PubMed ID: 28839342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder.
    Correll CU; Josiassen RC; Liang GS; Burke J; O'Brien CF
    Psychopharmacol Bull; 2017 Aug; 47(3):53-60. PubMed ID: 28839340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association study of Disrupted-In-Schizophrenia-1 gene variants and tardive dyskinesia.
    Lu JY; Tiwari AK; Zai GC; Rastogi A; Shaikh SA; Müller DJ; Voineskos AN; Potkin SG; Lieberman JA; Meltzer HY; Remington G; Wong AHC; Kennedy JL; Zai CC
    Neurosci Lett; 2018 Nov; 686():17-22. PubMed ID: 30118782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain dopamine-serotonin vesicular transport disease and its treatment.
    Rilstone JJ; Alkhater RA; Minassian BA
    N Engl J Med; 2013 Feb; 368(6):543-50. PubMed ID: 23363473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of dopaminergic and serotonergic genes with tardive dyskinesia in patients with chronic schizophrenia.
    Segman RH; Goltser T; Heresco-Levy U; Finkel B; Shalem R; Schlafman M; Yakir A; Greenberg D; Strous R; Lerner A; Shelevoy A; Lerer B
    Pharmacogenomics J; 2003; 3(5):277-83. PubMed ID: 14583797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tardive dyskinesia: placing vesicular monoamine transporter type 2 (VMAT2) inhibitors into clinical perspective.
    Citrome L
    Expert Rev Neurother; 2018 Apr; 18(4):323-332. PubMed ID: 29557243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.